Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 5—May 2008

Leishmania (Leishmania) amazonenis Infection, Suriname

On This Page
Article Metrics
citations of this article
EID Journal Metrics on Scopus

Cite This Article

Appendix Figure

Thumbnail of Infiltrated lesions on the patient's hands A) before and B) 70 days after treatment began.

Appendix Figure. Infiltrated lesions on the patient's hands A) before and B) 70 days after treatment began.

To the Editor: A 17-year-old man was seen at the Dermatology Service in Paramaribo (Suriname) with a skin condition that he had had since he was 5 years of age. The condition consisted of multiple cutaneous ulcerations, nodules, and fibrotic plaques disseminated on his face, limbs, and trunk, and subcutaneous nodules on lymph-draining tracts on his hands, arms, and legs (Appendix Figure, panel A). He had lived his entire life in an inland village, located at Brokopondo Lake (central-eastern Suriname); he had never traveled outside the country. The diagnosis of cutaneous leishmaniasis (CL, a parasitic disease caused by the protozoa Leishmania) was presumed. The patient received pentamidine therapy in 1997, 1998, and 2005, but without sustained clinical effect. Rapid screening tests for HIV were negative (Determine [Abbott Laboratories, Tokyo, Japan] and Unigold [Trinity Biotech, Co. Wicklow, Ireland]). In 2006, the diagnosis of CL was confirmed with histopathology, culture, and PCR. The parasite was identified by a PCR restriction fragment length polymorphism method on the small subunit–internal transcribed spacer genes (1) and by multilocus enzyme electrophoresis at the National Reference Center of Leishmania (Montpellier, France).

After promising results were obtained with miltefosine in a patient with anergic diffuse cutaneous leishmaniasis (ADCL) in Venezuela (2), the patient received 150 mg/day oral miltefosine (Impavido, Zentaris, Germany) for 98 days and the lesional parasite load was quantified with quantitative nucleic acid sequence-based amplification (3). Skin biopsy specimens were collected from 1 target lesion before treatment; during treatment at day 14, day 28, day 42 (all in duplicate); and at day 70 (single biopsy).

The strain causing infection (MHOM/SR/2006/SP100) was identified as Leishmania (Leishmania) amazonensis, and the enzymatic profile was equal to L. (L.) amazonensis zymodeme MON-41. Histopathology showed large macrophages containing abundant Leishmania amastigotes and few lymphocytes and plasma cells without granuloma formation. A considerable clinical improvement was observed during the first 2 months of therapy. The lesions slowly decreased in size and duration. At day 70, all ulcerative lesions were re-epithelialized, without signs of infiltration or lymphangitis (Appendix Figure, panel B). At start of treatment, parasite counts of 360,000 and 310,000 parasites per biopsy were detected; these counts decreased to 0 parasites/biopsy at day 70. Histopathologic studies at day 70 showed no Leishmania bodies, a dense lymphocytic and plasma cellular infiltrate, and fibrosis. Apart from mild elevation of creatine and urea during treatment, no subjective or adverse side effects were reported.

L. (L.) amazonensis causes CL and 2 very serious manifestations of CL, disseminated cutaneous leishmaniasis (DCL) and ADCL (4). Both forms are histopathologically characterized by heavily parasitized macrophages and an absence of cell-mediated immune responses in therapy-naive patients (4). ADCL is resistant to any form of therapy, and cell-mediated immune responses never seem to occur. In contrast, the cell-mediated immune response in DCL can eventually arise upon therapy response, even in patients with previous therapy failures (4). The therapy response in DCL patients is histopathologically characterized by the appearance of a lymphocytic and plasma cellular infiltrate. The diagnosis of DCL is plausible in our patient based on the histopathologic findings before, during, and after therapy; the clinical picture (erythematous infiltrated plaques, lymphadenitis, and lymphangitis), and the favorable therapy response. He was last seen 7 months after end of therapy, at which time new lesions had not developed.

In general, L. (L.) amazonensis infection is rare in humans (5). In French Guiana, bordering the eastern side of Suriname, few patients (≈1.9%) are reported to be infected with this species (5). However, the sandfly vector of L. (L.) amazonensis, Lutzomyia flaviscutellata, was detected earlier in Suriname (6), which may indicate transmission of L. (L.) amazonensis infection to humans by means of the bite of this sandfly in Suriname. Our patient had no history of transfusion or intravenous drug use.

Many gold diggers from the northern part of Brazil work and travel in Suriname and are familiar with CL. In the Brazilian State Pará, a region bordering Suriname in the South, the infection rate with L. (L.) amazonensis is high (34.8%) (7). It is thus conceivable that infected gold diggers from that area have introduced L. (L.) amazonensis into Suriname. Our patient used to live in a village where many Brazilian gold diggers worked around the time that his skin lesions developed. Migration of laborers is associated with an increased risk for CL infection (8). The zymodeme MON-41 is widespread in Central America and the northern part of South America, and has been reported in Venezuela, Brazil, Panama, French Guiana, and Colombia (F. Pratlong and J.P. Dedet, Montpellier International Cryobank of Leishmania, pers. comm., 2007). Therefore, speculations on the exact origin of the infection need to be made cautiously.



Miltefosine (Impavido) was kindly donated by Zentaris (Germany) at the request of Pieter van Thiel. We thank J.P Dedet, W.R. Faber, and H.D.F.H. Schallig for critical reading of the manuscript.

This work was supported by a grant from the Netherlands Foundation for the Advancement of Tropical Research (WOTRO contract 96-210).


Wendy van der Meide*Comments to Author , Henry de Vries†‡, Francine Pratlong§, Allard van der Wal†, and Leslie Sabajo¶
Author affiliations: *Royal Tropical Institute, Amsterdam, the Netherlands; †Academic Medical Center, Amsterdam, the Netherlands; ‡Health Service Amsterdam, Amsterdam, the Netherlands; §Centre National de Référence des Leishmania and Université Montpellier, Montpellier, France; ¶Dermatology Service, Paramaribo, Suriname



  1. Rotureau  B, Ravel  C, Couppié  P, Pratlong  F, Nacher  M, Dedet  JP, Use of PCR-restriction fragment length polymorphism analysis to identify the main New World Leishmania species and analyze their taxonomic properties and polymorphism by application of the assay to clinical samples. J Clin Microbiol. 2006;44:45967. DOIPubMedGoogle Scholar
  2. Zerpa  O, Blanco  B, Kannee  C, Ulrich  M, Sindermann  H, Engel  J, Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report. Int J Dermatol. 2006;45:7513. DOIPubMedGoogle Scholar
  3. van der Meide  WF, Schoone  GJ, Faber  WR, Zeegelaar  JE, de Vries  HJ, Ozbel  Y, Quantitative nucleic acid sequence-based assay as a new molecular tool for the detection and quantification of Leishmania parasites in skin biopsies. J Clin Microbiol. 2005;43:55606. DOIPubMedGoogle Scholar
  4. Silveira  FT, Lainson  R, Corbett  CE. Further observations on clinical, histopathological, and immunological features of borderline disseminated cutaneous leishmaniasis caused by Leishmania (Leishmania) amazonensis. Mem Inst Oswaldo Cruz. 2005;100:52534. DOIPubMedGoogle Scholar
  5. Rotureau  B, Ravel  C, Nacher  M, Couppié  P, Curtet  I, Dedet  JP, Molecular epidemiology of Leishmania (Viannia) guyanensis in French Guiana. J Clin Microbiol. 2006;44:46873. DOIPubMedGoogle Scholar
  6. Burgos  A, Hudson  J. Annotated list of the phlebotominae (diptera) of Suriname. Mem Inst Oswaldo Cruz. 1994;89:1718.
  7. Silveira  FT, Lainson  R, Shaw  JJ, De Souza  AA, Ishikawa  EA, Braga  RR. Cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis in Amazonian Brazil, and the significance of a negative Montenegro skin-test in human infections. Trans R Soc Trop Med Hyg. 1991;85:7358. DOIPubMedGoogle Scholar
  8. Rotureau  B, Joubert  M, Clyti  E, Djossou  F, Carme  B. Leishmaniasis among gold miners, French Guiana. Emerg Infect Dis. 2006;12:116970.PubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid1405.070433

Related Links


Table of Contents – Volume 14, Number 5—May 2008

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Wendy van der Meide, Koninklijk Instituut voor de Tropen/Royal Tropical Institute, KIT Biomedical Research, Meibergdreef 39, 1105 AZ, Amsterdam, the Netherlands;

Send To

10000 character(s) remaining.


Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.